Education
About Us
Working with TipRanks
Follow Us
Valneva SE (FR:VLA)
:VLA
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.18Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -1.66%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
Valneva's earnings call demonstrated strong revenue growth and significant regulatory achievements, notably in the chikungunya and Lyme disease vaccine programs. Improved gross margins and a robust cash position were also highlighted. However, concerns over adverse events related to IXCHIQ and a negative operating loss were noted as challenges.Company Guidance
During the call, Valneva provided guidance for fiscal year 2025, maintaining their product sales forecast at €170 million to €180 million and total revenues at €180 million to €190 million. The company aims to reduce operational cash burn by 50% for the year, with a target of achieving key milestones with existing cash reserves. Total R&D expenses are projected to be between €90 million and €100 million, offset by grant funding and R&D tax credits. Valneva aims for sustained profitability by 2027, contingent on the successful approval and commercialization of its Lyme disease vaccine. The company's cash position at the end of March 2025 was €153 million, with a significant reduction in cash used in operations from €28.4 million to €8.1 million compared to the previous year, primarily driven by increased sales and effective cost control.Strong Revenue Growth
Product sales reached €48.6 million, a 51.2% increase compared to the first quarter of the prior year. IXIARO sales were up 65.5% year-over-year, driven by increased sales to the US military and travel channels.
Regulatory Achievements
Key regulatory achievements for IXCHIQ include marketing authorization in the UK, submission for adolescent label extension, and marketing authorization in Brazil for the chikungunya vaccine.
Pipeline Progress
Valneva initiated the first vaccination in the Phase 2 infant study in Africa for the Shigella vaccine candidate and reported positive Phase 2 pediatric results for IXCHIQ.
Improved Gross Margins
IXIARO's gross margin improved to 72.6%, exceeding pre-COVID levels, while DUKORAL's gross margin reached 52.2%, up from below 40% in the first quarter of last year.
Significant Cash Position
Total cash and cash equivalents were €153 million, with operational cash burn significantly reduced from €28.4 million to €8.1 million compared to the prior year.
FR:VLA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:VLA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | €2.89 | €2.93 | +1.39% |
Mar 20, 2025 | €3.18 | €3.37 | +5.97% |
Nov 07, 2024 | €2.58 | €2.51 | -2.86% |
Aug 13, 2024 | €3.07 | €3.31 | +7.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Valneva SE (FR:VLA) report earnings?
Valneva SE (FR:VLA) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Valneva SE (FR:VLA) earnings time?
Valneva SE (FR:VLA) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Valneva SE stock?
The P/E ratio of Valneva is N/A.
What is FR:VLA EPS forecast?
FR:VLA EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.